glp-1 safety concerns Alarming rise in weight loss drug overdoses GLP1 medicines for weight loss

Another GLP-1R/GIPR/GCGR triple agonists, Efocipegtrutide (HM15211, Hanmi Pharmaceutical, Seoul, South Korea), has completed phase 1 for treatment of obesity (NCT03374241) and is currently in phase 2 for treatment of MASH (NCT04505436)

278 Additionally, MSCs-EVs modulate macrophage phenotypes and enhance polarization to the anti-inflammatory and highly phagocytic phenotype, which mainly depends on improved macrophage oxidative phosphorylation in mitochondria due to EV-mediated mitochondrial transfer

The APOE 4 allele remains the most significant genetic risk factor, enhancing susceptibility to both amyloid pathology and vascular dysfunction (Bonomi et al., 2024)

keep nighttime snacks early, small, and simple

289,290 The study results did not suggest that CPT has superior therapeutic effects compared to nonimmune plasma therapy, while convalescent plasma treatment seems safe and well tolerated

Taheri H, Malek M, Ismail-Beigi F et al (2020) Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial